Company intelligence / Profile preview

China Merchants Capital

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~260
Development stage: Other

Overview

China Merchants Capital (CMC) is a leading private equity and alternative investment firm, managing over US$43 billion AUM (as of 2017). Ranked among the largest PE firms in Asia-Pacific and globally, it is an affiliate of the state-owned China Merchants Group. While its core business is private equity across sectors, it actively invests in healthcare and biotech through portfolio companies and strategic partnerships, including companies like Immvira Bioscience Inc. and Xuanzhu Biopharm. Headquartered in China and Hong Kong, CMC focuses on investments across China, Asia-Pacific, and globally.

Industry: Investors

Partnerships

Cathay Biotech Inc. (strategic collaboration on bio-based materials, procurement targets, financing)PhIRDA (MOU on pharmaceutical innovation, industry funds)GLP (50% JV partner)

Beyond the preview

Go deeper on China Merchants Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Merchants Capital.

Explore the full profile